Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The provided evaluation content aligns with the FDA Klonopin label sections describing boxed/concomitant opioid benzodiazepine risks, including severity, mitigation (reserve use, lowest effective dose, minimum duration), and monitoring for sedation/respiratory depression.
Category Scores
Accurate Statements
Concomitant use of benzodiazepines (including Klonopin) with opioids may cause profound sedation, respiratory depression, coma, and death.
WARNING: RISKS FROM CONCONITANT USE WITH OPIOIDS; ... and WARNINGS: Risks from Concomitant Use with Opioids.
Because of these risks, reserve concomitant prescribing of benzodiazepines and opioids for patients for whom alternative treatment options are inadequate.
WARNING: RISKS FROM CONCONITANT USE WITH OPIOIDS; ... (reserve concomitant prescribing for whom alternative treatment options are inadequate).
Limit dosages and durations of concomitant use to the minimum required.
WARNING: ... (Limit dosages and durations to the minimum required) and WARNINGS: (prescribe the lowest effective dosages and minimum durations).
Follow patients closely for signs and symptoms of respiratory depression and sedation.
WARNING: ... (Follow patients for signs and symptoms of respiratory depression and sedation) and WARNINGS/WARNINGS drug-interaction related language.
The label states that concomitant use increases the risk of respiratory depression due to different CNS receptor actions (benzodiazepines at GABA-A sites; opioids at mu receptors).
PRECAUTIONS / Drug Interactions: Effect of Concomitant Use of Benzodiazepines and Opioids.
The evaluation indicates this opioid-concomitant risk guidance is supported by FDA labeling.
Supported by the cited FDA label warning and interaction sections included in the prompt.
Unsupported Statements
Contradictions
Important Omissions
The AI response does not separately address the boxed warning elements related to abuse/misuse/addiction and dependence/withdrawal reactions (beyond the opioid-concomitant risk claim).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The response accurately reflects on-label, high-severity boxed/major-warning content for benzodiazepine-opioid concomitant use and includes the label’s risk-mitigation and monitoring language; no conflicting or invented safety guidance is present.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Does not cover non-opioid-related boxed-warning components (abuse/misuse/addiction; dependence/withdrawal) that are also part of the provided boxed warning text.
Suggested Improvement
If summarizing the boxed warning comprehensively, include the abuse/misuse/addiction and dependence/withdrawal elements and their label-consistent mitigation (assessment for abuse risk; gradual taper to reduce withdrawal risk).